Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tumor collection/processing under physioxia uncovers highly relevant signaling networks and drug sensitivity.
Kumar B, Adebayo AK, Prasad M, Capitano ML, Wang R, Bhat-Nakshatri P, Anjanappa M, Simpson E, Chen D, Liu Y, Schilder JM, Colter AB, Maguire C, Temm CJ, Sandusky G, Doud EH, Wijeratne AB, Mosley AL, Broxmeyer HE, Nakshatri H. Kumar B, et al. Among authors: schilder jm. Sci Adv. 2022 Jan 14;8(2):eabh3375. doi: 10.1126/sciadv.abh3375. Epub 2022 Jan 12. Sci Adv. 2022. PMID: 35020422 Free PMC article.
Cell Origins of High-Grade Serous Ovarian Cancer.
Kim J, Park EY, Kim O, Schilder JM, Coffey DM, Cho CH, Bast RC Jr. Kim J, et al. Among authors: schilder jm. Cancers (Basel). 2018 Nov 12;10(11):433. doi: 10.3390/cancers10110433. Cancers (Basel). 2018. PMID: 30424539 Free PMC article. Review.
Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.
Tew WP, Sill MW, Walker JL, Secord AA, Bonebrake AJ, Schilder JM, Stuckey A, Rice L, Tewari KS, Aghajanian CA. Tew WP, et al. Among authors: schilder jm. Gynecol Oncol. 2018 Nov;151(2):257-263. doi: 10.1016/j.ygyno.2018.08.027. Epub 2018 Aug 31. Gynecol Oncol. 2018. PMID: 30177462 Free PMC article. Clinical Trial.
Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
Monk BJ, Sill MW, Walker JL, Darus CJ, Sutton G, Tewari KS, Martin LP, Schilder JM, Coleman RL, Balkissoon J, Aghajanian C. Monk BJ, et al. Among authors: schilder jm. J Clin Oncol. 2016 Jul 1;34(19):2279-86. doi: 10.1200/JCO.2015.65.8153. Epub 2016 May 23. J Clin Oncol. 2016. PMID: 27217446 Free PMC article. Clinical Trial.
A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
Bender D, Sill MW, Lankes HA, Reyes HD, Darus CJ, Delmore JE, Rotmensch J, Gray HJ, Mannel RS, Schilder JM, Hunter MI, McCourt CK, Samuelson MI, Leslie KK. Bender D, et al. Among authors: schilder jm. Gynecol Oncol. 2015 Sep;138(3):507-12. doi: 10.1016/j.ygyno.2015.07.018. Epub 2015 Jul 15. Gynecol Oncol. 2015. PMID: 26186911 Free PMC article. Clinical Trial.
Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
Alvarez EA, Brady WE, Walker JL, Rotmensch J, Zhou XC, Kendrick JE, Yamada SD, Schilder JM, Cohn DE, Harrison CR, Moore KN, Aghajanian C. Alvarez EA, et al. Among authors: schilder jm. Gynecol Oncol. 2013 Apr;129(1):22-7. doi: 10.1016/j.ygyno.2012.12.022. Epub 2012 Dec 20. Gynecol Oncol. 2013. PMID: 23262204 Clinical Trial.
29 results